Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. - Mansfield AS; Wei Z; Mehra R; Shaw AT; Lieu CH; Forde PM; Drilon AE; Mitchell EP; Wright JJ; Takebe N; Sharon E; Hovelson D; et al. (NPJ precision oncology, 2022)